Successful management of recurrent pregnancy-related thrombotic thrombocytopaenia purpura in a renal transplant recipient

Nephrology Dialysis Transplantation

Volumn 25, Issue 7, 2010, Pages 2378-2380

  Lam, Kimberly ^a   Martlew, Vanessa ^b   Walkinshaw, Steve ^c   Alfirevic, Zarko ^d   Howse, Matthew ^a  

^a ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b NATIONAL HEALTH SERVICE   (United Kingdom)

^c LIVERPOOL WOMEN S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

ADAMTS 13; pregnancy; renal transplant; thrombotic thrombocytopaenic purpura

Indexed keywords

AZATHIOPRINE; FRESH FROZEN PLASMA; IMMUNOGLOBULIN G ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCTAPLAS; PREDNISOLONE; TACROLIMUS; UNCLASSIFIED DRUG; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CASE REPORT; CHRONIC KIDNEY FAILURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HEMOLYTIC ANEMIA; HUMAN; HYPERTENSION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; PLASMAPHERESIS; PREECLAMPSIA; PREGNANCY DISORDER; PRIORITY JOURNAL; PROTEINURIA; RECURRENT DISEASE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; BLOOD; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; PREGNANCY; PREGNANCY COMPLICATIONS; PROCEDURES; PURPURA, THROMBOTIC THROMBOCYTOPENIC; TREATMENT OUTCOME;

ADAM PROTEINS; ADULT; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; PLASMA EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE; TREATMENT OUTCOME;

EID: 77954341282     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq228     Document Type: Article

References (11)

1. Molvarec A et al. Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia. Thromb Haemost 2009; 101: 305-311
2. Furlan M et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-1584 (Pubitemid 28536132)
3. Zheng XL et al. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytope-nic purpura. Blood 2004; 103: 4043-4049
4. Sanchez-Luceros A et al. von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women. Thromb Haemost 2004; 92: 1320-1326
5. Scully M et al. Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpura. Blood Coagul Fibrinolysis 2006; 17: 459-463
6. Hayward CP et al. Treatment outcomes in patients with adult throm-botic thrombocytopenic purpura-hemolytic uremic syndrome. Arch Intern Med 1994; 154: 982-987
7. Wurzei JM. TTP lesions in placenta but not fetus. N Engl J Med 1979; 301: 503-504
8. Allford SL et al. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 2003; 120: 556-573
9. Schmidt RJ, Venkat KK, Dumler F. Hemolytic-uremic syndrome in a renal transplant recipient on FK 506 immunosuppression. Transplant Proc 1991; 23: 3156-3157
10. Pham PT et al. Cyclosporine and tacrolimus-associated thrombotic microangiopathy. Am J Kidney Dis 2000; 36: 844-850
11. Crew RJ et al. De novo thrombotic microangiopathy following treatment with sirolimus: report of two cases. Nephrol Dial Transplant 2005; 20: 203-209